{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:29:37Z","timestamp":1787574577153,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Verrucous epidermal nevus is a benign epidermal hamartoma associated with somatic mosaic mutations, which shows poor response to conventional therapies and has a high risk of recurrence. To date, there are no standardized treatment guidelines for this condition. In recent years, targeted treatments for specific gene mutations have provided new directions for the clinical management of this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      We report a case of a 13-year-old child with verrucous epidermal nevus in whom genetic testing revealed an\n                      <jats:italic>HRAS<\/jats:italic>\n                      mosaic mutation. The child showed poor response to conventional treatments, including surgical excision, topical retinoic acid cream, and oral acitretin. However, after treatment with topical 0.5% (w\/w) sirolimus ointment, the child\u2019s skin lesions showed reduced area, thinning, improved pigmentation, and decreased roughness, and no local or systemic adverse reactions were observed during the 6-month treatment period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that topical sirolimus may represent a potentially effective therapeutic option for patients with verrucous epidermal nevus who are refractory to conventional therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1932228","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:07:46Z","timestamp":1787573266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical sirolimus for the treatment of verrucous epidermal nevus associated with an HRAS mosaic mutation: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiu-ju","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-yan","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-ju","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/ijd.12948","article-title":"Dermoscopy of verrucous epidermal nevus: large brown circles as a novel feature for diagnosis","volume":"55","author":"Carbotti","year":"2016","journal-title":"Int J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.jid.2021.02.765","article-title":"Molecular genetic dissection of inflammatory linear verrucous epidermal Naevus leads to successful targeted therapy","volume":"141","author":"Riachi","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-genet-121415-121955","article-title":"Mosaicism in cutaneous disorders","volume":"51","author":"Lim","year":"2017","journal-title":"Annu Rev Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"20707","DOI":"10.5070\/d31912020707","article-title":"Verrucous epidermal nevus","volume":"19","author":"Kim","year":"2013","journal-title":"Dermatol Online J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical Sirolimus therapy for facial Angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamadermatol.2025.2205","article-title":"Postzygotic gain-of-function variant in TRPM4 and inflammatory linear verrucous epidermal nevus","volume":"161","author":"Liu","year":"2025","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaad.2021.08.029","article-title":"Topical sirolimus therapy for nevus sebaceus and epidermal nevus: a case series","volume":"87","author":"Zhou","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1046\/j.1523-1747.2000.00182.x","article-title":"Mosaicism for ATP2A2 mutations causes segmental Darier's disease","volume":"115","author":"Sakuntabhai","year":"2000","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jamadermatol.2025.5414","article-title":"De novo germline L858R EGFR variants and generalized acanthosis Nigricans","volume":"162","author":"Jiang","year":"2026","journal-title":"JAMA Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The role of mTOR Signaling as a therapeutic target in cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/ijms23031693","article-title":"Predominant role of mTOR Signaling in skin diseases with therapeutic potential","volume":"23","author":"Karagianni","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jmedgenet-2011-100637","article-title":"Keratinocytic epidermal nevi are associated with mosaic RAS mutations","volume":"49","author":"Hafner","year":"2012","journal-title":"J Med Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2350-12-79","article-title":"Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation","volume":"12","author":"Bygum","year":"2011","journal-title":"BMC Med Genet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1684\/ejd.2013.2088","article-title":"Localized linear epidermolytic epidermal nevus of male genitalia with a recurrent keratin 10 mutation, p.Arg156His","volume":"23","author":"Uchiyama","year":"2013","journal-title":"Eur J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jid.2016.11.016","article-title":"Inflammatory linear verrucous epidermal nevus with a Postzygotic GJA1 mutation is a mosaic Erythrokeratodermia Variabilis et Progressiva","volume":"137","author":"Umegaki-Arao","year":"2017","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"E132","DOI":"10.1210\/jc.2013-2813","article-title":"Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23","volume":"99","author":"Avitan-Hersh","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1158\/1078-0432.CCR-24-1928","article-title":"Cancer in multilineage mosaic RASopathies due to pathogenic variants in HRAS or KRAS: a systematic review and meta-analysis","volume":"30","author":"Windrich","year":"2024","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/10600280231182421","article-title":"A review of topical sirolimus for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"58","author":"Dao","year":"2024","journal-title":"Ann Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jaad.2018.10.070","article-title":"Topical use of mammalian target of rapamycin inhibitors in dermatology: a systematic review with meta-analysis","volume":"80","author":"Leducq","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1932228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:07:47Z","timestamp":1787573267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1932228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":21,"alternative-id":["10.3389\/fmed.2026.1932228"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1932228","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1932228"}}